NewsBenzingaSolstice投资4900万美元扩展其在纽约州布法罗的研发能力;纽约州帝国发展局将通过纽约Excelsior就业计划提供最高140万美元的绩效型税收抵免,以支持该项投资 Solstice投资4900万美元扩展其在纽约州布法罗的研发能力;纽约州帝国发展局将通过纽约Excelsior就业计划提供最高140万美元的绩效型税收抵免,以支持该项投资 Benzinga 2026.10.09 15:42 (GMT+0) Open on Benzinga Other news 'China Taps US AI Models To Train Homegrown Rivals As Chip Curbs Bite' - Reuters Exclusive 'US Presses UN Agency Over Taiwan Flight Restrictions, China Hits Back' - Reuters Exclusive 'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century' Reported Earlier, NextNRG Q3 EPS $(6.88) Misses $(6.00) Estimate, Sales $26.715M Miss $28.087M Estimate Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen Aytu BioPharma Stock Climbs 44% After-Hours: Here's Why
'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century'
Reported Earlier, NextNRG Q3 EPS $(6.88) Misses $(6.00) Estimate, Sales $26.715M Miss $28.087M Estimate
Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen